Perfil personal
Research Interests
Dr. Zinner’s work and research interests include:
- Developing neoadjuvant and induction chemo-immune and molecularly targeted therapy regimens in surgery and radiation in the treatment of lung and head and neck cancer patients to reduce long-term morbidity and increase overall survival.
- Working toward the development of a KRAS program in lung cancer, which Kentucky and the region are especially well-placed to lead nationally.
- Increasing the odds of long-term survival and well-being in newly diagnosed and recurrent advanced stage lung and head and neck cancer using novel combinations of existing or newer therapeutics.
Cuantificación de educación / académica
Post Doctoral Fellow, University Of Texas Health Science Center
1999
Residency, Thomas Jefferson University
1996
Doctor of Medicine, Georgetown University
1993
Bachelor of Arts, University Of California - Berkeley
1986
Experiencia relacionada con los ODS de las Naciones Unidas
En 2015, los estados miembros de las Naciones Unidas acordaron 17 Objetivos de Desarrollo Sostenible (ODS) para erradicar la pobreza, proteger el planeta y garantizar la prosperidad para todos. El trabajo de esta persona contribuye al logro de los siguientes ODS:
-
Good health and well being
Huella digital
- 1 Perfiles similares
Colaboraciones y áreas de investigación principales de los últimos cinco años
-
25-HN-45-JJ (61186372HNC3001): A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants with Treatment-Na?ve Recurre
Arnold, S. M. (PI) & Zinner, R. (Former PI)
Janssen Research and Development LLC
2/2/26 → 2/2/28
Proyecto: Research project
-
25-LUN-142-AZ (D702FC00001): A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small
Zinner, R. (PI)
AstraZeneca Pharmaceuticals LP (domestic)
6/18/25 → 6/18/27
Proyecto: Research project
-
22-LUN-130-MSD (MK-7339 -013-03): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Conc
Hao, Z. (PI) & Zinner, R. (Former PI)
Merck Sharp & Dohme Corporation
1/13/23 → 10/25/26
Proyecto: Research project
-
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Arnold, S. M. (PI) & Zinner, R. (Former PI)
Mirati Therapeutics Incorporated
11/20/20 → 8/16/26
Proyecto: Research project
-
Uncovering Hidden Marginalized Populations in Lung Cancer Screening via Latent Class Analysis
Yoshino, T., Morita, S. X., Zinner, R. G. & Kato, H., abr 2026, En: Mayo Clinic Proceedings. 101, 4, p. 613-625 13 p.Producción científica: Article › revisión exhaustiva
-
In-Silico Predictions of Drug Resistance in Lung Cancers With EGFR Mutation
Imam, I., Abbas, U. L., Gosser, C. M., Brainson, C. F., de Jong, W., Liu, X., Moseley, H. N. B., Qing, S., Zhang, S., Zinner, R. & Ellingson, S. R., jun 20 2025, PASC 2025 - Platform for Advanced Scientific Computing Conference, Proceedings. (PASC 2025 - Platform for Advanced Scientific Computing Conference, Proceedings).Producción científica: Conference contribution › revisión exhaustiva
Acceso abierto -
L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds
Imam, I. A., Al Adawi, S., Liu, X., Ellingson, S., Brainson, C. F., Moseley, H. N. B., Zinner, R., Zhang, S. & Shao, Q., mar 2025, En: Proteins: Structure, Function and Bioinformatics. 93, 3, p. 673-683 11 p.Producción científica: Article › revisión exhaustiva
Acceso abierto6 Citas (Scopus) -
Motivating Adherence to Symptom Reporting among Patients with Cancer: Pilot Study
Donawa, A., Millan, J., Millan, L., Reeves, T., Lopez-Tucux, R., Shafagati, N., Arays, R., Zinner, R. & Baker, C. E., 2025, 2025 IEEE 21st International Conference on Body Sensor Networks, IEEE BSN 2025. (2025 IEEE 21st International Conference on Body Sensor Networks, IEEE BSN 2025).Producción científica: Conference contribution › revisión exhaustiva
-
Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Subbiah, V., Yu, P. P., Sarangarajan, R., Kiebish, M. A., Rodrigues, L. O., Miller, G. M., Akmaev, V. R., Luan, S., McCook, J. P., Tanna, N., Reilly, T., Chen, E., Bussberg, V., Ravipaty, S., Vishnudas, V. K., Gesta, S., Lucius, D., Bruce, C., Hazarika, S. & Lyng, A. y 18 otros, , ene 2025, En: Cancer Research Communications. 5, 12, p. 2207-2223 17 p.Producción científica: Article › revisión exhaustiva
Acceso abierto2 Citas (Scopus)